Celgene has entered into a strategic collaboration with MedImmune to develop and commercialize an anti-PD-L1 inhibitor, MEDI4736, for hematologic malignancies.
MEDI4736 is a human monoclonal antibody directed against programmed cell death ligand 1 (PD-L1), which helps tumors avoid detection by the immune system.
Tumor cells use PD-L1 to turn off the immune system just as it begins to mount a response against them.
Searching for more deal information? Current Partnering offers the following options:
|
MEDI4736 helps turn the immune system back on, allowing it to continue its attack on cancer.
Celgene will collaborate with AstraZeneca to develop the anti-PD-L1 antibody MEDI4736 in hematology and make an upfront payment of $450 million.
Celgene will lead clinical development across all new clinical trials within the collaboration and be responsible for all costs associated with these trials until December 31, 2016, after which it is responsible for 75% of these costs.
Celgene will also be responsible for the global commercialization of approved MEDI4736 indications in hematology, and will receive royalty rates starting at 70 percent of worldwide sales from all uses in hematology.
Royalty rates will decrease gradually to 50 percent over a period of four years after the first date of commercial sales.
This collaboration agreement will become effective upon the expiration or termination of the applicable waiting periods under all applicable antitrust laws.
This strategic collaboration will initially focus on the development of MEDI4736 as combination therapy with Celgene's pipeline of products and other novel agents for hematologic disorders.
Over time, the collaboration could expand to include other assets.
For further deal information visit Current Agreements (subscription required)
Related
Scorecard: Top partnering deals by value in 2015
View: Top pharmaceutical companies
View: Top biotech companies
Reports: Browse our extensive deal making report portfolio
anim.gif?rand=5003)
